Key Takeaways, With Data for Maryland FDA approvals vary by drug: There are currently three GLP-1s on the market that the FDA ...

Study authors point to semaglutide medication and “behavior changes” as possible reasons for the drop in obesity rates in the ...

Results of the study indicate that Black women in the U.S., ages 66-75, saw the largest decrease in obesity between 2022-2023 ...

A few years ago, West Virginia, which has the highest obesity rate in the nation, quietly began a small and unusual pilot ...

Biden officials recently proposed allowing Medicare to start covering GLP-1 medications to treat obesity. It's unclear ...

Obesity rates in the US dropped slightly in 2023 for the first time in over a decade, with rates falling from 46% to 45.6%. A ...

Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...

Doctors might be slow to admit it, but Ozempic and other GLP-1 drugs are making dieting and exercise obsolete.

Obesity is down in the US for the first time in a decade. A new study suggests weight-loss drugs may explain why.

Popular GLP-1 medications like semaglutide in Ozempic and Wegovy help people lose weight, but what should patients know about ...

Semaglutide and similar medications could be key players in bending the curve but enduring change ultimately hinges on a ...

Obesity dipped slightly in U.S. adults last year, research found — the first time in more than a decade that the country has ...